Aetas Pharma Overview
- Year Founded
-
2000
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
2ndary - Private
Aetas Pharma General Information
Description
Developer of cardiac and renal ailment drugs intended to better treat arrhythmias and overactive bladders. The company develops drugs that improve cardiac and renal functions and is engaged in the development of therapeutic agents for atrial fibrillation in heart disease, enabling clinicians to provide patients with better treatment for heart and kidney diseases.
Contact Information
Website
www.aetaspharma.comCorporate Office
- 1-7 Kanda Ogawacho
- Chiyoda-ku
- Tokyo, 101-0052
- Japan
Corporate Office
- 1-7 Kanda Ogawacho
- Chiyoda-ku
- Tokyo, 101-0052
- Japan
Aetas Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 01-Jun-2026 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC | 01-Jan-2021 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC | 31-May-2019 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC | 30-Nov-2016 | Completed | Startup | |||
| 1. Seed Round | 01-Jan-2015 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Aetas Pharma Patents
Aetas Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4019089-A1 | Method for producing optically active 1, 4-benzothiazepine-1-oxide derivative | Inactive | 22-Jul-2019 | ||
| EP-4019089-A4 | Method for producing optically active 1, 4-benzothiazepine-1-oxide derivative | Inactive | 22-Jul-2019 | ||
| US-12252483-B2 | Method for producing optically active 1, 4-benzothiazepine-1-oxide derivative | Active | 22-Jul-2019 | ||
| US-20220324856-A1 | Method for producing optically active 1, 4-benzothiazepine-1-oxide derivative | Active | 22-Jul-2019 | ||
| WO-2021015221-A1 | Method for producing optically active 1, 4-benzothiazepine-1-oxide derivative | Inactive | 22-Jul-2019 | C07D417/06 |
Aetas Pharma Signals
Aetas Pharma FAQs
-
When was Aetas Pharma founded?
Aetas Pharma was founded in 2000.
-
Where is Aetas Pharma headquartered?
Aetas Pharma is headquartered in Tokyo, Japan.
-
What is the size of Aetas Pharma?
Aetas Pharma has 10 total employees.
-
What industry is Aetas Pharma in?
Aetas Pharma’s primary industry is Drug Discovery.
-
Is Aetas Pharma a private or public company?
Aetas Pharma is a Private company.
-
What is Aetas Pharma’s current revenue?
The current revenue for Aetas Pharma is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process